Evidence map›Paper›PMID 29454560›Full record

ArticleThe Journal of investigative dermatology2018

Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood.

Alexander V Sorokin, Anthony F Domenichiello, Amit K Dey, Zhi-Xin Yuan, Aditya Goyal, Shawn M Rose, Martin P Playford, Christopher E Ramsden, Nehal N Mehta

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03889938 (Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis), which is not on this map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03889938 unknown statusnot on this mapstarted 2019, after this paper: background citation

Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

TypeobservationalSponsorAssiut UniversityRan2019 to 2020Enrolled60ConditionsPsoriasisArmsSerum and urinary assessment
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Therapeutic effect ofFrontiers in pharmacology · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alexander V SorokinSection of Inflammation and Cardiometabolic Diseases, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anthony F DomenichielloLipid Mediators, Inflammation, and Pain Unit, Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Amit K DeySection of Inflammation and Cardiometabolic Diseases, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Zhi-Xin YuanLipid Mediators, Inflammation, and Pain Unit, Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Aditya GoyalSection of Inflammation and Cardiometabolic Diseases, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Shawn M RoseBristol-Myers Squibb Clinical Development, Princeton, New Jersey, USA.
Martin P PlayfordSection of Inflammation and Cardiometabolic Diseases, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Christopher E RamsdenLipid Mediators, Inflammation, and Pain Unit, Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA; Intramural Program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA; FOODplus Research Centre, School of Agriculture Food and Wine, The University of Adelaide, Adelaide, Australia.
Nehal N MehtaSection of Inflammation and Cardiometabolic Diseases, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: nehal.mehta@nih.gov.
National Institutes of Health · USBristol-Myers Squibb (United States) · US

Funding

The roles of lipid mediators in inflammation, pain, and neuro-degenerationZIAAG000453 · NIA · NATIONAL INSTITUTE ON AGING · PI RAMSDEN, CHRISTOPHER · 2017 to 2025
$35.1M
Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic disease (PACI) InitiativeZIAHL006193 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2014 to 2023
$25.0M
In-vitro and Pre-clinical Translational Studies of Inflammation and AtherosclerosisZIAHL006235 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2018 to 2023
$6.7M
Intramural NIH HHS Z99 AG999999
6 · The paper itself

Abstract

Psoriasis is a chronic immune-mediated disease that represents a unique model for investigating inflammation at local and systemic levels. Bioactive lipid mediators (LMs) are potent compounds reported to play a role in the development and resolution of inflammation. Currently, it is not known to what extent these LMs are involved in psoriasis pathophysiology and related metabolic dysfunction. Here, we use targeted and untargeted liquid chromatography-tandem mass spectrometry approaches to quantify LMs in skin and peripheral blood from psoriasis patients and compared them with those of healthy individuals. Lesional psoriasis skin was abundant in arachidonic acid metabolites, as 8-, 12- and 15-hydroxyeicosatetraenoic acid, compared with adjacent nonlesional and skin from healthy individuals. Additionally, a linoleic acid-derived LM, 13-hydroxyoctadecadienoic acid, was significantly increased compared with healthy skin (607.9 ng/g vs. 5.4 ng/g, P = 0.001). These psoriasis skin differences were accompanied by plasma decreases in antioxidant markers, including glutathione, and impaired lipolysis characterized by lower concentrations of primary and secondary bile acids. In conclusion, our study shows that psoriasis skin and blood have disease-specific phenotype profiles of bioactive LMs represented by omega-6 fatty acid-oxidized derivatives. These findings provide insights into psoriasis pathophysiology that could potentially contribute to new biomarkers and therapeutics.

Indexed as

Lipid MetabolismAdultChromatography, High Pressure LiquidFatty Acids, Omega-6FemaleHealthy VolunteersHumansMaleMetabolomicsMiddle AgedPsoriasisSkinTandem Mass SpectrometryFatty Acids, Omega-6

Identifiers

PMID29454560
PMCPMC6121727
OpenAlexW2789093894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.